Precision Medicine in Oncology®

Martin Steffen, MD, PhD, developed phosphorylation signatures that discriminate between lung tumors and normal lung, and is developing signatures for the prediction of therapy response.

Dr. Jose Baselga from Massachusetts General Hospital Describes the Advantages of Dual Blockade

Cancer treatment is moving from a one-size-fits-all approach to personalized medicine, which means matching the right drug with the right tumor characteristics.

Andre Goy, MD, MS, treats lymphoma patients at New Jersey's largest cancer center, Goy, 54, is also a translational researcher widely known for his work showing the first-ever evidence of activity of bortezomib.

Although the use of tumor markers to evaluate patients with breast cancer is well established, the nuances involved in such testing are growing along with the emergence of novel assays and fresh research findings.

Established in 1973 as the University of Pennsylvania's Cancer Center and subsequently renamed in 2002, the Abramson Cancer Center is a world leader in research, patient care, and education.

Dr. Ranee Mehra from Fox Chase Cancer Center Discusses DNA Repair Enzymes

A look at tweaking the corruptive influence of the virus information code to selectively corrupt cancer cells while sparing (normal) cells that do not have a specific cancer phenotype.

Ezra E. W. Cohen, MD, has focused on the role of EGFR inhibitors in much of his research into head and neck cancers.

Dr. Maurie Markman from Cancer Treatment Centers of America Discusses Diagnostic Molecular Testing

Analysts are optimistic about Exact Sciences financial losses because they reflect the heavy investment in clinical trials for a new noninvasive colorectal cancer test.

Dr. Ezra Cohen from the University of Chicago Discusses Head and Neck Cancer Pathways

The Cleveland Clinic has long been at the forefront of cutting-edge medicine and research. The center's reputation as a world leader in a multitude of fields, including oncology, is undisputed.

This year marks more than 20 years of research into the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway.

If IKK kinase, a group of inhibitory proteins, activity is not regulated properly, tumors in the body have the ability to migrate and proliferate.

The scientific strategy of attacking cancer by thwarting angiogenesis has been on a roller coaster ride for the past 40 years

Josep Tabernero, MD, is actively involved in clinical research with molecular targeted therapies, with a focus on EGFR-family and PI3K-Akt-mTOR pathway inhibitors, in phase II and III studies with new chemotherapy agents in gastrointestinal tumors.

There are at least 7 drugs specifically targeting VEGF in later-stage clinical trials that have been the subject of presentations at oncology conferences in recent months.

Ezra E. W. Cohen, MD, is a physician and translational researcher at the University of Chicago Medical Center, that focuses on epidermal growth factor receptor (EGFR) inhibitors.

Dr. Andre Goy from John Theurer Cancer Center Explains the Concept of Personalized Medicine

Dr. Sean Grimm from Northwestern University, Feinberg School of Medicine on MGMT as a Predictive Marker in Brain Cancer

Dr. Lori Goldstein from Fox Chase Cancer Center on Fulvestrant in Metastatic Breast Cancer

Primary care physicians in the US adhere poorly to established guidelines for genetic counseling and testing for women who are at high risk of breast and ovarian cancer.

Dr. Gordon B. Mills from the University of Texas MD Anderson Cancer Center Discusses the Field of Targeted Therapeutics

Advances in the understanding of tumor biology and a robust drug development pipeline are combining to form a 'perfect storm' of opportunity for personalized cancer research to make a leap forward.